Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons

Neurogastroenterology and Motility

Volumn 24, Issue 12, 2012, Pages

  Balestra, B ^a   Vicini, R ^a   Cremon, C ^b   Zecchi, L ^b   Dothel, G ^b   Vasina, V ^b   De Giorgio, R ^b   Paccapelo, A ^b   Pastoris, O ^a   Stanghellini, V ^b   Corinaldesi, R ^b   De Ponti, F ^b   Tonini, M ^a   Barbara, G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Enteric nervous system; Inflammatory mucosal mediators; Irritable bowel syndrome; Mast cells; Twitch contractions

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; CAPSAZEPINE; HISTAMINE H1 RECEPTOR; N (4 ISOPROPYLPHENYL) 2 (1,2,3,6 TETRAHYDRO 1,3 DIMETHYL 2,6 DIOXO 7H PURIN 7 YL)ACETAMIDE; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SERINE PROTEINASE; SEROTONIN 1 RECEPTOR; SEROTONIN 4 RECEPTOR;

ADULT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CHOLINERGIC NERVE CELL; COLON MUCOSA; CONTROLLED STUDY; DESCENDING COLON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE CONTRACTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MAST CELL; MYENTERIC PLEXUS; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANIMALS; CHOLINERGIC NEURONS; COLON; CULTURE MEDIA, CONDITIONED; FEMALE; GUINEA PIGS; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; MAST CELLS; MOTOR NEURONS; MYENTERIC PLEXUS;

EID: 84870300639     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12000     Document Type: Article

References (50)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51(Suppl. 1): i41-4.
3. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-96.
4. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-88.
5. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
6. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-5.
7. Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.
8. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18: 6-17.
9. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-47.
10. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
11. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-34.
12. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.
13. Chang L, Adeyemo M, Karagiannides I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-72.
14. Bassotti G, Villanacci V, Nascimbeni R et al. Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther 2011; 34: 92-9.
15. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 2009; 58: 1300-11.
16. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
17. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671-4.
18. Paton WD, Zar MA. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 1968; 194: 13-33.
19. Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther 2000; 293: 321-8.
20. Liu YJ, Jackson DM, Blackham A. Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations. Eur J Pharmacol 1996; 303: 187-92.
21. Schemann M, Michel K, Ceregrzyn M, Zeller F, Seidl S, Bischoff SC. Human mast cell mediator cocktail excites neurons in human and guinea-pig enteric nervous system. Neurogastroenterol Motil 2005; 17: 281-9.
22. Vergnolle N. Clinical relevance of proteinase activated receptors (pars) in the gut. Gut 2005; 54: 867-74.
23. Steck N, Mueller K, Schemann M, Haller D. Bacterial proteases in IBD and IBS. Gut 2011; doi: 10.1136/gutjnl-2011-300775.
24. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007; 87: 659-797.
25. Suzuki R, Furuno T, Okamoto K, Teshima R, Nakanishi M. ATP plays a role in neurite stimulation with activated mast cells. J Neuroimmunol 2007; 192: 49-56.
26. Di Virgilio F, Chiozzi P, Ferrari D et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001; 97: 587-600.
27. Wareham K, Vial C, Wykes RC, Bradding P, Seward EP. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. Br J Pharmacol 2009; 157: 1215-24.
28. Sharkey KA, Mawe GM. Neuroimmune and epithelial interactions in intestinal inflammation. Curr Opin Pharmacol 2002; 2: 669-77.
29. Burnstock G. Purinergic receptors and pain. Curr Pharm Des 2009; 15: 1717-35.
30. Rong W, Keating C, Sun B, Dong L, Grundy D. Purinergic contribution to small intestinal afferent hypersensitivity in a murine model of postinfectious bowel disease. Neurogastroenterol Motil 2009; 21: 665-71.
31. Monro RL, Bertrand PP, Bornstein JC. ATP participates in three excitatory postsynaptic potentials in the submucous plexus of the guinea pig ileum. J Physiol 2004; 556: 571-84.
32. Bertrand PP, Bornstein JC. ATP as a putative sensory mediator: activation of intrinsic sensory neurons of the myenteric plexus via P2X receptors. J Neurosci 2002; 22: 4767-75.
33. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol 2004; 141: 1313-20.
34. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-9.
35. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465: 121-35.
36. Bartho L, Benko R, Patacchini R et al. Effects of capsaicin on visceral smooth muscle: a valuable tool for sensory neurotransmitter identification. Eur J Pharmacol 2004; 500: 143-57.
37. Geber C, Mang CF, Kilbinger H. Facilitation and inhibition by capsaicin of cholinergic neurotransmission in the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 277-83.
38. Bartho L, Holzer P, Lembeck F, Szolcsanyi J. Evidence that the contractile response of the guinea-pig ileum to capsaicin is due to release of substance P. J Physiol 1982; 332: 157-67.
39. Wood JD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology 2004; 127: 635-57.
40. Dekkers JA, Akkermans LM, Kroese AB. Effects of the inflammatory mediator prostaglandin E2 on myenteric neurons in guinea pig ileum. Am J Physiol 1997; 272: G1451-6.
41. Frieling T, Rupprecht C, Kroese AB, Schemann M. Effects of the inflammatory mediator prostaglandin D2 on submucosal neurons and secretion in guinea pig colon. Am J Physiol 1994; 266: G132-9.
42. Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008; 20: 900-7.
43. Buhner S, Li Q, Berger T et al. Submucous rather than myenteric neurons are activated by supernatants of mucosal biopsies from IBS patients. Neurogastroenterol Motil 2010; 22: 1.
44. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
45. Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988; 29: 342-5.
46. De Giorgio R, Barbara G, Furness JB, Tonini M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 2007; 28: 473-81.
47. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
48. Barbara G, Stanghellini V, Cremon C et al. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 2009; 27(Suppl. 1): 115-21.
49. Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-52.
50. Dunlop SP, Jenkins D, Spiller RC. Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol 2004; 16: 1011-5.